Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Sunpeaks Ventures, Inc. (OTCBB: SNPK) Featured By Small Cap Investment Research

(EMAILWIRE.COM, April 11, 2012 ) Los Angeles, CA -- Small Cap Investment Research (SmallCapInvestmentResearch.com), a developer, publisher and marketer of independent research products, announced today the release of an updated research report on Sunpeaks Ventures, Inc (OTCBB: SNPK) (“the Company”). Small Cap Investment Research has issued a “STRONG BUY” and a target price of $9.00 on shares of this company.



The report examines the potential continued growth of the Company as it continues to gain market share, and examines the outlook for short and long-term investors. “We were pleased to have the opportunity to report on this company and the industry factors that affect it. The report presents a great overview of the Company and its potential for the long-term with a constantly improving industry dynamic.” – Small Cap Investment Research.



Recently, Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") announced that HDS has signed a Letter of Intent with PharmaLife® for placement of Clotamin® with leading pharmacies in the Russian Federation.



The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma. PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.

The entire report can be found on http://www.smallcapinvestmentresearch.com/featured-companies/ .



About Small Cap Investment Research:

Small Cap Investment Research specializes in providing readers with an in-depth analysis of undervalued companies. The company’s role as an independent research analyst firm is to “separate the wheat from the chaff” and help investors receive unbiased, thought-provoking, and quality investment research. SCIR’s philosophy in research is to encapsulate realistic investment ratings, target prices, and forward-looking financial models. The reports contain hard-hitting, meticulously researched facts on companies, their fundamentals, and their industries, validating a company’s prospects and enabling the reader to objectively evaluate the company’s value. The media and savvy investors alike view this model as how investment research needs to be performed devoid of any partiality.



About Sunpeaks Ventures, Inc.:

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.



Forward-Looking Statements

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of Sunpeaks Ventures, Inc. (OTCBB: SNPK) can be found in the filings of Sunpeaks Ventures, Inc. with the U.S. Securities and Exchange Commission.



Release of Liability: Through use of this website viewing or using you agree to hold SCIR, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. We have been compensated six thousand dollars for this SNPK report. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCIR encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCIR makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.



Indepedent Research Investment
Derrick Brazinski
3104567798
dbrazinski@indedentresearchinvestment.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

Ebola could kill 90,000 in Liberia by year-end unless efforts scaled up: study
24 Oct 2014 at 5:27am
By Magdalena Mis LONDON (Thomson Reuters Foundation) - Efforts to control the Ebola virus in Liberia must be quickly and dramatically scaled up or tens of thousands of people will die in the coming months, said a study published on Friday. Nearly 4,900 deaths have been recorded across West Africa since the virus was first detected in Guinea in March, according to the World Health Organization. Liberia has been the hardest hit of the countries most affected by the virus, with 2,705 deaths and 4,665 recorded cases. ...

WHO expects around 200,000 Ebola vaccine doses by mid: 2015
24 Oct 2014 at 5:26am
GENEVA/LONDON (Reuters) - The World Health Organization (WHO) set out plans on Friday for speeding up development and deployment of experimental Ebola vaccines, saying hundreds of thousands of doses should be ready for use in West Africa by the middle of 2015. The Geneva-based United Nations health agency confirmed that two leading vaccine candidates are already in human clinical trials, and said another five experimental vaccines were also being developed and would begin clinical trials next year. "Before the end of first half of 2015..we could have available a few hundred thousand doses. ...


Futures decline on weak Amazon results, Ebola concern
24 Oct 2014 at 5:24am

By Chuck Mikolajczak NEW YORK (Reuters) - U.S. stock index futures fell on Friday, putting the S&P 500 on track to trim its weekly advance, following disappointing earnings from Amazon and as the first diagnosed case of Ebola in New York City raised concerns about the spread of the virus. Amazon plunged 9.9 percent to $282.23 in premarket trade after the online retailer's sales projections for the crucial holiday quarter disappointed Wall Street and third-quarter results missed forecasts. Microsoft , up 2.6 percent at $46. ...



Doctor with Ebola in New York hospital after return from Guinea
24 Oct 2014 at 5:22am

By Ellen Wulfhorst and Sebastien Malo NEW YORK (Reuters) - A doctor who worked in West Africa with Ebola patients was in an isolation unit in New York City on Friday after testing positive for the virus, becoming the fourth person diagnosed with the disease in the United States and the first in its largest city. Dr. Craig Spencer, 33, was placed in a quarantined unit at Bellevue Hospital on Thursday, six days after returning from Guinea, renewing public jitters about transmission of the disease and rattling financial markets. ...


Canadian consulate in Istanbul gets package containing yellow powder: Turkish...
24 Oct 2014 at 5:08am
ISTANBUL (Reuters) - Turkish authorities on Friday launched an investigation after an unidentified yellow powder was found in a package sent to the Canadian consulate in Istanbul. "The letter containing a yellow substance was examined in line with regular procedures," Turkey's disaster management agency, AFAD, said in a statement. One Canadian consulate employee came directly into contact with the suspicious package and six others had indirect exposure, the statement said. The German and Belgian consulates also received similar packages containing the yellow powder, Turkish media reported. ...

EU backs drug for rare sun intolerance from Australia's Clinuvel
24 Oct 2014 at 5:06am
LONDON (Reuters) - European patients with a rare genetic disease that causes intolerance to sunlight should soon have a new treatment option, following a green light for a drug from Australia's Clinuvel Pharmaceuticals. The biotech company is pinning its hopes on Scenesse, the first medicine for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP). After exposure to sunlight, patients with EPP feel a stinging pain in sun-exposed skin and prolonged exposure can lead to an incapacitating pain, often followed by redness and swelling. ...


Beds at Ebola treatment units empty in Liberia
24 Oct 2014 at 5:03am

MONROVIA, Liberia (AP) ? Even as Liberians fall ill and die of Ebola, many beds in treatment centers are empty because of the government's order that the bodies of all suspected Ebola victims in the capital be cremated, authorities have determined.


Europe backs continued use of Ariad Pharma's leukemia drug
24 Oct 2014 at 5:03am
(Reuters) - European regulators recommended continued use of Ariad Pharmaceuticals Inc's cancer drug Iclusig in its already approved indications to treat certain kinds of leukemia. However, the European Medicines Agency (EMA) recommended additional warnings in Iclusig's European product information to minimize the risk of vascular events, Ariad said on Friday. The decision follows a positive recommendation from the EMA's Pharmacovigilance Risk Assessment Committee, which said earlier this month that the benefits of Iclusig continued to outweigh its risks. ...


After 1st Ebola case in NYC, 3 others quarantined
24 Oct 2014 at 5:02am

NEW YORK (AP) ? A doctor who became New York City's first Ebola patient was praised for getting treatment immediately upon showing symptoms, and health officials stressed that the nation's most populous city need not fear his wide-ranging travel in the days before his illness began.



AstraZeneca cancer drug pipeline gets boost from European green light
24 Oct 2014 at 4:47am

By Ben Hirschler LONDON (Reuters) - AstraZeneca's cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer. The green light from the European Medicines Agency (EMA) for olaparib, or Lynparza, is welcome news since the product hit a road bump in June when a U.S. panel voted against its accelerated approval. AstraZeneca has flagged the medicine as a potential $2 billion-a-year seller. Olaparib blocks an enzyme involved in cell repair and is designed for patients with certain hereditary gene mutations. ...


Pakistan detects more polio cases on awareness day
24 Oct 2014 at 4:36am
ISLAMABAD (AP) ? World Health Organization says three more polio cases have surfaced in Pakistan, bringing the number of those affected by the crippling disease in the country this year to 220.


New York confirms first Ebola case
24 Oct 2014 at 4:28am

New York confirmed the first case of Ebola in the largest city in the United States as the EU dramatically ramped up aid Friday to contain the killer epidemic ravaging west Africa. The EU announcement of one billion euros ($1.3 billion) for the worst-hit countries comes as fears of a spread of the virus grew, with the first confirmed case in Mali, where a two-year-old girl has tested positive. The World Health Organization (WHO), which has warned the Ebola crisis in west Africa "remains of great concern", held talks Thursday on efforts to ensure access to and funding for potential vaccines. The New York case is a doctor who recently returned from treating Ebola patients in Guinea, the epicenter of the world's worst outbreak of the disease.



Cameron: EU secures $1.25 billion for Ebola fight
24 Oct 2014 at 3:56am

BRUSSELS (AP) ? British Prime Minister David Cameron says that the European Union and its 28 member nations have secured 1 billion euros ($1.25 billion) to fight the Ebola crisis in West Africa.



WHO sending Ebola experts to Mali, 43 people monitored for virus
24 Oct 2014 at 3:47am

GENEVA (Reuters) - The World Health Organization (WHO) said on Friday it was sending more experts to help Mali fight Ebola, a day after the first case of the disease was confirmed there. Malian authorities said on Thursday a two-year-old girl who had traveled to neighboring Guinea was infected -- making Mali the sixth West African country to be touched by the worst outbreak on record of the hemorrhagic fever, which has killed almost 4,900 people. . ...


Hikma Pharma shares slip on FDA warning for Portugal plant
24 Oct 2014 at 3:45am
(Reuters) - Drugmaker Hikma Pharmaceuticals Plc said the U.S. health regulator had raised issues related to environmental monitoring at its plant in Portugal, which some analysts said accounts for about a quarter of the company's U.S. injectibles sales. Shares in the Jordanian company fell more than 6 percent on Friday as the warning added to disappointment of weak branded drug sales and a case filed by Takeda Pharmaceutical Co against the approval of Hikma's drug for gout flares. Hikma's stock was the top percentage loser on the FTSE-250 Midcap Index in the morning. ...

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC